Search:
You do not have permission to access this chart.
Please Sign Up or Login
News for Summit Therapeutics Inc. (SMMT)
minutes ago | Banggood.com
58 minutes ago | Aliexpress.com
4 days ago | GlobeNewsWire
a month ago | GlobeNewsWire
a month ago | GlobeNewsWire
2 months ago | GlobeNewsWire
2 months ago | Zacks Investment Research
2 months ago | Benzinga
2 months ago | Benzinga
2 months ago | Pulse2
3 months ago | GlobeNewsWire
3 months ago | GlobeNewsWire
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridium difficile infection (CDI). The company’s lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; and DDS-04 series to treat Enterobacteriaceae. Summit Therapeutics Inc. was founded in 2003 and is based in Cambridge, Massachusetts.